CureVac exercises options in strategic collaboration with myNEO.

CureVac has exercised its options on a selected set of potential cancer vaccine targets identified by myNEO under the existing partnership agreement. Two option fee payments were triggered to myNEO.

By applying its AI-based neoantigen discovery ImmunoEngine platform, myNEO has discovered a broad collection of novel cancer targets, which it is using to develop breakthrough off-the-shelf cancer vaccine therapeutics internally and with strategic partners.

GHENT, Belgium and Tubingen, Germany/Boston, USA – November 22, 2023 – myNEO N.V. (myNEO) and CureVac N.V. (Nasdaq CVAC) announced today that CureVac has exercised two exclusive options on selected sets of potential cancer vaccine antigen targets. Since the initiation of the myNEO-CureVac partnership in May 2022, both companies have closely collaborated and have achieved several important milestones. In this collaboration, myNEO has used its advanced AI-powered technology platform to analyze extensive biological datasets and has identified a collection of novel shared antigen targets associated with two cancer indications.

The identified antigen targets demonstrated strong immunogenicity in undisclosed preclinical studies. CureVac will select the most promising targets for validation and consideration for the design of potential mRNA cancer vaccine candidates.

Cedric Bogaert, CEO of myNEO, said: “We are excited by the rapid progress achieved in this collaborative program with CureVac. CureVac's decision to exercise its options is a strong validation of our ImmunoEngine platform and the results it has generated. This milestone achievement is indicative of our position as a leading company in the field of novel cancer target discovery. We very much look forward to continuing our highly productive partnership with CureVac.”